Physician profile
Christopher A Carpenter
NPI 1508846023
$1,501.34
in general payments reported to CMS, 2019-2025
26 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $88.14 · 2021: $204 · 2022: $24.87 · 2023: $192 · 2024: $502 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $396.33 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $195.28 | 2019-2025 | Wegovy |
| Abbvie INC. | $134.05 | 2021-2024 | Qulipta |
| Lilly USA, LLC | $103.55 | 2019-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $80.77 | 2023-2025 | Veozah |
| Edwards Lifesciences Corporation | $66.48 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $61.59 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $54.86 | 2021-2025 | |
| Pfizer INC. | $52.42 | 2024 | |
| Amgen INC. | $38.51 | 2019-2025 | Repatha, Otezla |
| Medtronic, INC. | $31.49 | 2024 | Intellis Adaptivestim |
| Grifols USA, LLC | $28.17 | 2025 | Prolastin-C Liquid |
| Viiv Healthcare Company | $24.33 | 2023 | Apretude |
| Allergan, INC. | $23.50 | 2020 | |
| Hologic Sales and Service, LLC | $22.62 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.93 | 2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $21.23 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.72 | 2024 | Edarbi |
| Jazz Pharmaceuticals INC. | $17.88 | 2021 | |
| Fidia Pharma USA INC. | $17.09 | 2020 | |
| Eisai INC. | $15.75 | 2021 | |
| Exeltis, USA INC. | $15.53 | 2023 | Slynd |
| Exact Sciences Corporation | $15.10 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.71 | 2024 | Quviviq |
| Amarin Pharma, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.